CAS: 603-00-9; 7-(2-Hydroxypropyl)-1,3-Dimethyl-3,7-Dihydro-1H-Purine-2,6-Dione

该化合物是一种化学化合物,被归类为Xanthine衍生物,主要以其支气管特性著称;它经常用于治疗哮喘和慢性阻塞性肺病(COPD)等呼吸系统疾病;由于它能够放松支气管滑动肌肉,改善空气流;该化合物具有分子配方,包括碳,氢,氮和氧等元素,有助于其药理活动; 代氧素在水中表现出中等溶解性,通常以口服形式施用; 其行动机制涉及磷化酶抑制,导致循环氨基氨基甲酸碱水平的升高,从而推动溴化变异; 此外, 催产素可能会产生轻微的二分泌效应; 与任何药物一样,都必须考虑到潜在的副作用,其中可能包括胃肠扰动和心血管影响;

结构式图片

欧盟法规

ECHA物质C&L通报REACH预注册

上下游产品

CAS号10226-64-9 1,3-dimethyl-7-... | CAS号58-55-9 茶碱 | CAS号19686-73-8 1-溴-2-丙醇 | CAS号127-00-4 1-氯-2-丙醇 | CAS号75-56-9 环氧丙烷

合成工艺路线路线简述

    7-Acetonyltheophyllin置于乙醇,镍体系中,100.0~120.0 °C,8.83 Mpa 条件下,反应生成 羟丙茶碱
    参考文献:Zelnik Et Al.,Bulletin De La Societe Chimique De France,1956,P. 1773,1775
    标题:Zelnik Et Al.,Bulletin De La Societe Chimique De France,1956,P. 1773,1775

    海关参考信息

    专利信息


    专利号:US-7173021-B2
    优先权日:2004-09-02
    标题:Synthesis of temozolomide esters as potent anticancer pro-drugs for topical and transdermal applications in treatments of cancers
    发明人:WANG YONGFENG; CONWAY BARBARA R; SUPPASANSATORN PANASSAYA
    权利人:TIANJIN NORTH PHARM SCI TECH C
    摘要:This invention relates to the use of temozolomide esters (4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxylate esters) Formula 1 as potent anticancer pro-drugs for treatment of cancers by topical and transdermal applications, and to a novel process for synthesis of temozolomide esters by a direct esterification of temozolomide acid (3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxylic acid) with a halogeno-aliphatic compound in presence of a base, or with an alcohol in presence of a dehydrate agent

    专利号:EP-1334714-B1
    优先权日:2002-02-07
    标 题:Use of ascorbic acid to stergthen the dermal-epidermal junction
    发明人:BERNERD FRANCOISE
    权利人:OREAL
    摘要:Cosmetic use of a composition (A), comprising ascorbic acid or its analog (I) in a cosmetic medium, is claimed for improving the cohesion of the epidermis-dermis junction, promoting the synthesis of tenascin and/or promoting the synthesis of type VII collagen. Independent claims are included for: (i) use of (I) for the production of a pharmaceutical (specifically dermatological) composition (B) for treating disorders associated with deficiency in cohesion of the epidermis-dermis junction, synthesis of tenascin and/or synthesis of type VII collagen; and (ii) use of (I) in the culture medium for reconstructed skin, for improving the cohesion of the epidermis-dermis junction in the reconstructed skin.

    专利号:US-2008287407-A1
    优先权日:2003-12-10
    标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use
    发明人:GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI
    权利人:NITROMED INC
    摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.

    专利号:US-2004005342-A1
    优先权日:2002-02-07
    标题 :Topical administration of ascorbic acid to reinforce the cohesion of the dermo-epidermal junction
    发明人:BERNERD FRANCOISE
    权利人:OREAL
    摘要:The present invention relates to the pharmaceutical or cosmetic use of a composition comprising, in a pharmaceutically or cosmetically acceptable medium, ascorbic acid or an analogue thereof to reinforce the cohesion of the dermo-epidermal junction. n The invention also relates to the pharmaceutical or cosmetic use of a composition comprising, in a pharmaceutically or cosmetically acceptable medium, ascorbic acid or an analogue thereof to increase the synthesis of tenascin and/or collagen VII. n The invention also relates to the use of ascorbic acid or of an analogue thereof to reinforce the cohesion of the dermo-epidermal junction of reconstructed skins.

    专利号:CN-110184247-A
    优先权日:2019-05-09
    标题 :Alfalfa melatonin synthesis gene MsASMT and its application in regulating the synthesis of melatonin and flavonoids in plants

    专利号:EP-1541127-B1
    优先权日:2003-12-10
    标题 :Use of modulators of aquaglyceroporins as slimming agents
    发明人:CALS-GRIERSON MARIE-MADELEINE
    权利人:OREAL
    摘要:Adipose aquaglyceroporin (AQPap) modulators that stimulate the AQPap activity of adipocytes are used in cosmetic compositions as slimming agents for reducing the volume of adipocytes, are new. Independent claims are also included for: (1) cosmetic composition comprising an adipose aquaglyceroporin modulator as above and a lipolytic agent; (2) use of escin, proanthocyanidins, diosgenin and ginkgo extracts for modulating the aquaglyceroporins of adipose tissue. ACTIVITY : Anorectic. No biological data given. MECHANISM OF ACTION : Adipose aquaglyceroporin modulator; phosphodiesterase inhibitor; alpha -2 receptor inhibitors, neuropeptide Y inhibitors, LDL or VLDL receptor synthesis inhibitors, beta receptor activators, G-protein activators, glucose transport blockers, adenylcyclase activator. No biological data given.
    上海万代制药有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    电话:021-58890705👤
    ⚠️参考联系方式
    销售经理: 徐玮经理
    联系电话:021-58890705
    手机号码: 13386099188
    传真号码: 021-51036620
    上海金山区干巷金张公路2068号
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    上海金山区干巷金张公路2068号
    ⚠️ 未注册 · 未认证企业
    注册入口 声明: 数据来源:本内容基于各搜索引擎等公开数据整理,仅作展示用。请自行辨别 📄若企业需抹除相关内容或, 请联系方我们,我们即刻栓除。
    上海人民制药溶剂厂
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    电话:+86-21-59172860👤
    ⚠️参考联系方式
    地址:上海真南路5218号. 邮编:201802
    电话:+86-21-59172860
    传真:+86-21-59126214

    联系人:李总
    手机:18616148353
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    上海真南路5218号
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Borowiecki P, Paprocki D, Dudzik A, Plenkiewicz J. Chemoenzymatic Synthesis of Proxyphylline Enantiomers. J Org Chem. 2016 Jan 15;81(2):380-95. doi: 10.1021/acs.joc.5b01840. Epub 2016 Jan 6. doi: 10.1016/j.ijpharm.2012.01.056. Epub 2012 Feb 6.

    合成参考文献


    摘要:Drugs in Japan, -(1178), 1995
    摘要:S72 | NTUPHTW | Pharmaceutically Active Substances from National Taiwan University | DOI:10.5281/zenodo.3955664
    参考文献:10.1021/jm980469t
    摘要:Cavallaro RA, Filocamo L, Galuppi A, Galione A, Brufani M, Genazzani AA. Potentiation of cADPR-induced Ca(2+)-release by methylxanthine analogues. J Med Chem. 1999 Jul 15;42(14):2527–34. doi: 10.1021/jm980469t.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知